Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Rhea-AI Summary
Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026. A live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET, with a recorded replay available on the company website and archived for about 90 days.
The company will provide a corporate update during the call; investors can access the live webcast via the company’s investor site.
Positive
- None.
Negative
- None.
News Market Reaction – TARS
In the Feb 18 session, TARS gained 0.78%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Conference participation | Neutral | -3.9% | Announced fireside chat at BTIG Ophthalmology Day with webcast details. |
| Nov 05 | Conference participation | Neutral | -0.2% | Management participation in Guggenheim healthcare conference with webcast access. |
| Nov 04 | Earnings release | Positive | -4.6% | Q3 2025 results with strong XDEMVY sales growth and narrowed net loss. |
| Oct 28 | Earnings date set | Neutral | -0.1% | Scheduled Q3 2025 earnings webcast and outlined replay availability. |
| Aug 27 | Conference participation | Neutral | +0.6% | Planned presentations at two September 2025 investor healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Neutral scheduling and conference updates have typically seen muted, small price moves, while fundamentally positive earnings results have coincided with short-term share price declines.
Over the last six months, Tarsus has frequently issued conference and event notices, as well as earnings updates. Neutral items such as investor conference participation and prior earnings date announcements around Aug 27, Oct 28, and Nov 5, 2025 saw minimal price impact. By contrast, the Nov 4, 2025 Q3 2025 results release, which highlighted strong XDEMVY growth and improving losses, was followed by a 4.62% decline. Today’s earnings date notice fits the pattern of largely informational scheduling updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
